Pyxis Oncology
Yahoo Finance • 23 days ago
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chie... Full story
Yahoo Finance • last month
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and nec... Full story
Yahoo Finance • 2 months ago
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (F... Full story
Yahoo Finance • 3 months ago
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 monotherapy trial expanded to include coh... Full story
Yahoo Finance • last year
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Ken Kobay... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of NAPCO Security Technologies Inc. (NASDAQ: PYXS)
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of NAPCO Security Technologies Inc. (NASDAQ: PYXS) concerning possible breaches of fiduciary duty. To obtain additional informa... Full story
Yahoo Finance • last year
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 (a fully human immu... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of fiduciary duty. To obtain additional information, go to... Full story
Yahoo Finance • 2 years ago
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for four dif... Full story
Yahoo Finance • 2 years ago
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upc... Full story
Yahoo Finance • 2 years ago
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validat... Full story
Yahoo Finance • 2 years ago
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 30, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compens... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ:PYXS) concerning possible breaches of fiduciary duty. To obtain additional information, go to:... Full story
Yahoo Finance • 2 years ago
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara Sullivan... Full story
Yahoo Finance • 2 years ago
Pyxis Oncology Announces FDA Clearance of Two IND Applications
FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, animmunotherapy product candidate Phase 1 clinical trials of PYX-201 and PYX-106 will evaluate the safety and anti-tumor activity... Full story
Yahoo Finance • 2 years ago
Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update
Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components Gains exclusive rights to Pfizer’s ADC technology platform and toolkit to certain licensed targets; Initial multi-tar... Full story
Yahoo Finance • 3 years ago
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update
• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities • Appointed Rachel Humphrey, M.D., a senior biotech executive with extensive experience in drug... Full story
Yahoo Finance • 3 years ago
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sul... Full story
Yahoo Finance • 3 years ago
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial resu... Full story
Yahoo Finance • 3 years ago
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
- Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse model - - Preclinical data support IND filing in 2H 2022 - CAMBRIDGE, Mass. and NEWARK, Del. and NANJING, China, April 08, 2022 (GLOB... Full story
